The Impact of Interferon Lambda 3 Gene Polymorphism on Natural Course and Treatment of Hepatitis C
Host genetic factors may predict the outcome and treatment response in hepatitis C virus (HCV) infection. Very recently, three landmark genome-wide association studies identified single nucleotide polymorphisms near the interleukin 28B (IL28B) region which were more frequent in responders to treatme...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2012/849373 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832554237739925504 |
|---|---|
| author | F. Bellanti G. Vendemiale E. Altomare G. Serviddio |
| author_facet | F. Bellanti G. Vendemiale E. Altomare G. Serviddio |
| author_sort | F. Bellanti |
| collection | DOAJ |
| description | Host genetic factors may predict the outcome and treatment response in hepatitis C virus (HCV) infection. Very recently, three landmark genome-wide association studies identified single nucleotide polymorphisms near the interleukin 28B (IL28B) region which were more frequent in responders to treatment. IL28B encodes interferon (IFN)λ3, a type III IFN involved in host antiviral immunity. Favourable variants of the two most widely studied IL28B polymorphisms, rs12979860 and rs8099917, are strong pretreatment predictors of early viral clearance and sustained viral response in patients with genotype 1 HCV infection. Further investigations have implicated IL28B in the development of chronic HCV infection versus spontaneous resolution of acute infection and suggest that IL28B may be a key factor involved in host immunity against HCV. This paper presents an overview about the biological activity and clinical applications of IL28B, summarizing the available data on its impact on HCV infection. Moreover, the potential usefulness of IFNλ in the treatment and natural history of this disease is also discussed. |
| format | Article |
| id | doaj-art-95622900665549b680f04af57dd0a006 |
| institution | Kabale University |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-95622900665549b680f04af57dd0a0062025-02-03T05:52:02ZengWileyClinical and Developmental Immunology1740-25221740-25302012-01-01201210.1155/2012/849373849373The Impact of Interferon Lambda 3 Gene Polymorphism on Natural Course and Treatment of Hepatitis CF. Bellanti0G. Vendemiale1E. Altomare2G. Serviddio3Department of Medical and Occupational Sciences, C.U.R.E. Centre for Liver Disease Research and Treatment, University of Foggia, ItalyDepartment of Medical and Occupational Sciences, C.U.R.E. Centre for Liver Disease Research and Treatment, University of Foggia, ItalyDepartment of Medical and Occupational Sciences, C.U.R.E. Centre for Liver Disease Research and Treatment, University of Foggia, ItalyDepartment of Medical and Occupational Sciences, C.U.R.E. Centre for Liver Disease Research and Treatment, University of Foggia, ItalyHost genetic factors may predict the outcome and treatment response in hepatitis C virus (HCV) infection. Very recently, three landmark genome-wide association studies identified single nucleotide polymorphisms near the interleukin 28B (IL28B) region which were more frequent in responders to treatment. IL28B encodes interferon (IFN)λ3, a type III IFN involved in host antiviral immunity. Favourable variants of the two most widely studied IL28B polymorphisms, rs12979860 and rs8099917, are strong pretreatment predictors of early viral clearance and sustained viral response in patients with genotype 1 HCV infection. Further investigations have implicated IL28B in the development of chronic HCV infection versus spontaneous resolution of acute infection and suggest that IL28B may be a key factor involved in host immunity against HCV. This paper presents an overview about the biological activity and clinical applications of IL28B, summarizing the available data on its impact on HCV infection. Moreover, the potential usefulness of IFNλ in the treatment and natural history of this disease is also discussed.http://dx.doi.org/10.1155/2012/849373 |
| spellingShingle | F. Bellanti G. Vendemiale E. Altomare G. Serviddio The Impact of Interferon Lambda 3 Gene Polymorphism on Natural Course and Treatment of Hepatitis C Clinical and Developmental Immunology |
| title | The Impact of Interferon Lambda 3 Gene Polymorphism on Natural Course and Treatment of Hepatitis C |
| title_full | The Impact of Interferon Lambda 3 Gene Polymorphism on Natural Course and Treatment of Hepatitis C |
| title_fullStr | The Impact of Interferon Lambda 3 Gene Polymorphism on Natural Course and Treatment of Hepatitis C |
| title_full_unstemmed | The Impact of Interferon Lambda 3 Gene Polymorphism on Natural Course and Treatment of Hepatitis C |
| title_short | The Impact of Interferon Lambda 3 Gene Polymorphism on Natural Course and Treatment of Hepatitis C |
| title_sort | impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis c |
| url | http://dx.doi.org/10.1155/2012/849373 |
| work_keys_str_mv | AT fbellanti theimpactofinterferonlambda3genepolymorphismonnaturalcourseandtreatmentofhepatitisc AT gvendemiale theimpactofinterferonlambda3genepolymorphismonnaturalcourseandtreatmentofhepatitisc AT ealtomare theimpactofinterferonlambda3genepolymorphismonnaturalcourseandtreatmentofhepatitisc AT gserviddio theimpactofinterferonlambda3genepolymorphismonnaturalcourseandtreatmentofhepatitisc AT fbellanti impactofinterferonlambda3genepolymorphismonnaturalcourseandtreatmentofhepatitisc AT gvendemiale impactofinterferonlambda3genepolymorphismonnaturalcourseandtreatmentofhepatitisc AT ealtomare impactofinterferonlambda3genepolymorphismonnaturalcourseandtreatmentofhepatitisc AT gserviddio impactofinterferonlambda3genepolymorphismonnaturalcourseandtreatmentofhepatitisc |